

DECEMBER 2012 VIEW IN BROWSER

Dear Colleague,

The December monthly update of BNF and BNFC has now been published. Our e-newsletter provides insight into the most significant changes made to the BNF and BNFC, including guidance on a risk of fatal hyponatraemia with hypotonic intravenous infusions. In news, we draw attention to a new MedicinesComplete search function.

BNF Team

IN THIS ISSUE

How to purchase BNF	More >
Significant changes	More >
News	More >
Drug Safety Update	More >
Feedback on our e-newsletter	More >

How to purchase BNF



Purchase print copies

The Pharmaceutical Press Winter Sale is now on! Purchase the BNF at a saving of 40% on RRP. Visit the **Pharmaceutical Press website**.



Purchase a print subscription - and save up to 25%

A print subscription is the best way to ensure access to the latest copy of BNF as soon as it publishes. To order bulk subscriptions contact **pharmaceutical.press@rpharms.com**.



BNF online

Outside the UK, content is available via a subscription to MedicinesComplete. For more information contact **sales@medicinescomplete.com**

Significant changes

This month's changes to the clinical content of these publications are described in two parts:

- BNF update should be read by all users of the BNF
- BNFC update should be read by all users of the BNF for Children

BNF update

Palliative Care Update

The BNF Palliative care section has been reorganised and now includes new tables for opioid conversions. The new 'pain management with opioids' section has been organised to provide guidance on specific routes for pain management. The 'Equivalent doses of opioid analgesics' table has been expanded to include more drugs and routes; also included is a new buprenorphine table and updated fentanyl patch conversion table. For more information see **Prescribing in palliative care**.

Ceftazidime Dose

Changes have been made to the dose of ceftazidime. For further information see ceftazidime.

Other changes

Review other changes in the BNF here.

BNFC update

Risk of fatal hyponatraemia with hypotonic intravenous infusions

The use of hypotonic intravenous infusion fluids in children has been associated with fatal hyponatraemia. The guidance in BNFC section 9.2.2.1 has been updated to reflect recent recommendations from the MHRA/CHM (Drug Safety Update, October 2012). Sodium chloride 0.18% and glucose 4% intravenous infusion is now contra-indicated in children aged 16 years or less, except when initiated and maintained under expert medical supervision in paediatric specialist settings. For further information click on Electrolytes and water.

Other changes

To review changes in the BNFC, click on changes.

return to top

News

Improvements to MedicinesComplete interface

As part of an ongoing initiative to improve the user experience of MedicinesComplete, a new search function has been introduced. The search bar at the top of each page now features a drop-down list to the left, allowing the user to search other MedicinesComplete publications easily and from any



In addition, the header which contains the search bar now provides users with the option to 'attach' or 'float' the header (the latter meaning that it remains at the top of the browser window and is always visible while scrolling down a page). Users are able to select their preferred option from the settings list at the top right of the screen. return to top

Drug Safety Update



Drug Safety Update is a monthly newsletter from the MHRA and MedicinesComplete Commission on Human Medicine. Please follow this link to review this month's **Drug Safety Update**.

return to top

Feedback on our e-newsletter

Please let us know if there are any issues that you would like us to address in e-newsletters. We welcome your feedback. If you have any comments or suggestions please let us know. Subscribe to this newsletter.

return to top

Related Products









Copyright © 2012 BMJ Publishing Group Ltd and the Royal Pharmaceutical Society of Great Britain. All rights reserved.

Terms of use



Copyright © 2012 BMJ Publishing Group Ltd, the Royal Pharmaceutical Society of Great Britain and RCPCH Publications. All rights reserved.

Terms of use

If you do not wish to receive such mailings in the future please $\underline{\text{click here}}$ to unsubscribe.

Pharmaceutical Press, 1 Lambeth High Street, London, SE1 7JN, UK